EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

JAK Inhibitors in Rheumatoid Arthritis: Immunomodulatory Properties and Clinical Efficacy

Kajetan Kiełbowski iD, Paulina Plewa, Aleksandra Wiktoria Bratborska iD, Estera Bakinowska, Andrzej Pawlik iD

International Journal of Molecular Sciences · 30.07.2024 · 25 (15) · 8327

DOI: 10.3390/ijms25158327 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 30.07.2024. Verfasst von Kajetan Kiełbowski und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, Pomeranian Medical University, 70-111 Szczecin, Poland. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Janus Kinase Inhibitors, Janus Kinases. Die Arbeit wurde bisher 62-mal zitiert (Crossref) und nennt 154 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rheumatoid arthritis (RA) is a highly prevalent autoimmune disorder. The pathogenesis of the disease is complex and involves various cellular populations, including fibroblast-like synoviocytes, macrophages, and T cells, among others. Identification of signalling pathways and molecules that actively contribute to the development of the disease is crucial to understanding the mechanisms involved in the chronic inflammatory environment present in affected joints. Recent studies have demonstrated that the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway regulates the behaviour of immune cells and contributes to the progression of RA. Several JAK inhibitors, such as tofacitinib, baricitinib, upadacitinib, and filgocitinib, have been developed, and their efficacy and safety in patients with RA have been comprehensively investigated in a number of clinical trials. Consequently, JAK inhibitors have been approved and registered as a treatment for patients with RA. In this review, we discuss the involvement of JAK/STAT signalling in the pathogenesis of RA and summarise the potential beneficial effects of JAK inhibitors in cells implicated in the pathogenesis of the disease. Moreover, we present the most important phase 3 clinical trials that evaluated the use of these agents in patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidJanus Kinase InhibitorsJanus KinasesHumansSignal TransductionSTAT Transcription FactorsAnimalsAntirheumatic Agents

Stichwörter der Autor:innen

JAK inhibitorsJAK/STAT pathwayrheumatoid arthritis

Substanzen

Janus Kinase InhibitorsJanus KinasesSTAT Transcription FactorsAntirheumatic Agents

Autor:innen und Institutionen

  • Department of Physiology, Pomeranian Medical University, 70-111 Szczecin, Poland.
  • Institute of Biology, University of Szczecin, 71-412 Szczecin, Poland.
  • Department of Internal Medicine, Poznan University of Medical Sciences, 60-780 Poznan, Poland.

ORCID-Profile: Kajetan Kiełbowski, Aleksandra Wiktoria Bratborska, Andrzej Pawlik

Zitieren

APA

Kiełbowski, K., Plewa, P., Bratborska, A. W., Bakinowska, E., & Pawlik, A. (2024). JAK Inhibitors in Rheumatoid Arthritis: Immunomodulatory Properties and Clinical Efficacy. International Journal of Molecular Sciences, 25(15), 8327. https://doi.org/10.3390/ijms25158327

Vancouver

Kiełbowski K, Plewa P, Bratborska AW, Bakinowska E, Pawlik A. JAK Inhibitors in Rheumatoid Arthritis: Immunomodulatory Properties and Clinical Efficacy. International Journal of Molecular Sciences. 2024;25(15):8327. doi:10.3390/ijms25158327

BibTeX
@article{Kiebowski2024,
  author = {Kiełbowski, Kajetan and Plewa, Paulina and Bratborska, Aleksandra Wiktoria and Bakinowska, Estera and Pawlik, Andrzej},
  title = {JAK Inhibitors in Rheumatoid Arthritis: Immunomodulatory Properties and Clinical Efficacy},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {15},
  pages = {8327},
  doi = {10.3390/ijms25158327}
}
Kostenlos starten →